



RECEIVED
MAY 12 2003
PATENT
TECH CENTER
871A 600/2900

7
5/16/03
NW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

YUUSUKE NONOMURA

Serial No: 10/038,565

Filed: October 19, 2001

For: AN ORAL TREATMENT/CARE
AGENT

Art Unit: 1614

Examiner: Shep K. Rose

RESPONSE

Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In response to the communication from the Examiner dated March 4, 2003, it is respectfully requested that the Examiner consider the following remarks.

REMARKS

The Examiner has objected to the disclosure under 37 CFR 1.71 as being incomprehensible because the pages one and three are missing. Pursuant to MPEP section 608.01(p)(q), submitted herewith are copies of the page one and three together with an attorney's declaration, a certified copy of the priority document and a verified translation of the priority document.. Applicant respectfully submits that the pages one and three of the application filed are supported at pages 6 through 8 of the verified English translation. Therefore, it is respectfully requested that the enclosed copies of pages one and three of the application be accepted.

The Examiner has also raised certain questions. In reply thereto, yes the azithromycin is administered orally and ingested; while the amphotericin B is a syrup is applied to the inside of the mouth, but not ingested.